BioBridge Global Announces Formation Of Regenerative Medicine Advisory Board
BioBridge Global today announced the formation of a new Regenerative Medicine Advisory Board, composed of industry leaders with a wide range of scientific, product development and business experience, to support the organization’s continued growth in regenerative medicine.
BioBridge Global provides a wide range of blood, tissue and cellular source materials, products and services through its three operating entities: GenCure, QualTex Laboratories and the South Texas Blood & Tissue Center. These include blood and tissue collection, processing and distribution, biological testing, process engineering and biomanufacturing.
The initial members of the BioBridge Global Regenerative Medicine Advisory Board are:
- Phil Vanek PhD, General Manager of GE Healthcare’s Cell and Gene Therapy business strategy. Dr. Vanek also served as Head of Business Development for Cell Therapy and later as Head of Innovation for Lonza’s pharmaceutical division. Dr. Vanek received his doctorate in Biochemistry and Molecular Biology from Georgetown University.
- Gregory Bonfiglio JD, Founder and Managing Partner of Proteus LLC, an investment and advisory firm focused solely on regenerative medicine, and Chairman of the Board of the Centre for Commercialization of Regenerative Medicine in Toronto, Canada. In 2013, Bonfiglio was listed 14th among the Top 50 Stem Cell Influencers in the world.
- Kenneth Bertram MD, PhD, FACP, is the former Commander of the Walter Reed Army Institute of Research and Principal Assistant for Acquisition for the U.S. Army Medical Research and Materiel Command. Dr. Bertram is board certified in internal medicine and has been board- certified in hematology and medical oncology.
“We recruited these highly regarded individuals because of their deep understanding of regenerative medicine, including needs, opportunities, roadblocks and how the field may change in the future,” said Martin Landon, Chief Executive Officer of BioBridge Global. “As we advance our work at BioBridge Global, we are fortunate to have access to Phil, Greg and Ken, not only for their advice as industry leaders, but for their shared commitment to realizing the potential of regenerative medicine to heal and save lives.”